Genome Editing in Human iPS Cells to Study and Cure Disease
Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More
News
2022. 4. 1. Lanyu Huang joins the lab as a graduate student. Kayoko Shinozaki, Yuya Yasuda, and Kanata Imamura start thier BS theses in the lab.
2022. 3. 6. Our analysis of genome editing outcomes at the single cell level are out at bioRxiv.
2022. 2. 8. Daiki Kondo wins the best presentation award in the Institutional poster presentation competition.
2022. 1. 15. Comment on iPS cell therapy in Yomiuri Newspaper.
2021. 11. 25. Anri Saitoh wins the Ochanomizu University Outstanding Student Award in Biology.
2021. 11. 18. Kanata Imamura and Yuga Yasuda join the lab as interns.
2021. 11. 10. Miyaoka answers a question on liver regeneration in Kodomo no Kagaku (Kids' Science magazine).
We revealed surprising smilarlities between cardiomyopathy and neurodgenerative diseases such as ALS (PDF).
Press relsease by Cincinnati Children's Hospital.
2021. 10. 5. A review on CRISPR-Cas9 by Nakajima and Miyaoka is published in Clinical Immunology & Allergology (in Japanese)
2021. 9. 1. Miyaoka is now affiliated with Ochanomizu University as an associate professor
Upcoming
2022. 5. 16. R&D Support Center Co.,Ltd. Seminar (Talk)
2022. 10. 5. Karasuyama Public Seminar "What is PCR?" (Seminar)